431 50 Mölndal
A molecular toxicologist by training and a specialist in Computational Toxicology, Dr. Scott Boyer joined AstraZeneca in 1997 and has worked in several senior scientific, project and leadership roles, most recently as Chief Scientist, the highest scientific title in the company. He has been one of the principal architects of the Modeling and Simulation capability build within AZ which enhanced the company’s capability in all areas of Modeling and Simulation from molecular design to clinical trial design. Scott Boyer is currently Global Head of Molecular and Genetic Toxicology for AstraZeneca responsible for all mechanistic safety work and for the introduction of new safety technologies into drug safety studies.
Prior to joining AstraZeneca, he was at Pfizer Central Research in Groton specializing in reactive metabolite research to support INDs, new drug registration packages and marketed products. Scott Boyer received his postdoctoral training in Molecular Toxicology at the Institute for Environmental Medicine at the Karolinska Institute in Stockholm in the area of bioenergetics of compromised mitochondrial function. Prior to that, he performed his doctoral dissertation research at the University of Colorado in Boulder in the area of metabolic activation of xenobiotics to chemically reactive species, specifically focusing on the chemical mechanisms of the liver damage observed in acute cocaine poisoning.